scPharmaceuticals Inc has a consensus price target of $18.33, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Craig-Hallum, and HC Wainwright & Co. on March 14, 2024, September 7, 2023, and August 11, 2023. With an average price target of $18.67 between HC Wainwright & Co., Craig-Hallum, and HC Wainwright & Co., there's an implied 313.90% upside for scPharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
09/07/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 343.46% | Craig-Hallum | Chase Knickerbocker | → $20 | Initiates | → Buy | Get Alert |
08/11/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
08/02/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
07/19/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
06/08/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
05/11/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 343.46% | Maxim Group | Naz Rahman | $13 → $20 | Maintains | Buy | Get Alert |
05/11/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
03/23/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | → Buy | Get Alert |
01/27/2023 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 188.25% | SVB Leerink | Roanna Ruiz | $12 → $13 | Maintains | Outperform | Get Alert |
12/01/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 454.32% | Cowen & Co. | Ken Cacciatore | → $25 | Initiates | → Outperform | Get Alert |
11/10/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 299.11% | HC Wainwright & Co. | Douglas Tsao | $15 → $18 | Maintains | Buy | Get Alert |
11/10/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 166.08% | SVB Leerink | Roanna Ruiz | $11 → $12 | Maintains | Outperform | Get Alert |
10/21/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 210.42% | Jefferies | Glen Santangelo | → $14 | Assumes | → Buy | Get Alert |
10/11/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 143.9% | SVB Leerink | Roanna Ruiz | $6 → $11 | Upgrade | Market Perform → Outperform | Get Alert |
08/02/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | — | Maxim Group | Naz Rahman | — | Initiates | → Buy | Get Alert |
05/17/2022 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 33.04% | SVB Leerink | Roanna Ruiz | $5 → $6 | Maintains | Market Perform | Get Alert |
09/09/2021 | SCPH | Buy Now | scPharmaceuticals | $4.51 | 33.04% | SVB Leerink | Roanna Ruiz | — | Initiates | → Market Perform | Get Alert |
The latest price target for scPharmaceuticals (NASDAQ: SCPH) was reported by HC Wainwright & Co. on March 14, 2024. The analyst firm set a price target for $18.00 expecting SCPH to rise to within 12 months (a possible 299.11% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for scPharmaceuticals (NASDAQ: SCPH) was provided by HC Wainwright & Co., and scPharmaceuticals reiterated their buy rating.
The last upgrade for scPharmaceuticals Inc happened on October 11, 2022 when SVB Leerink raised their price target to $11. SVB Leerink previously had a market perform for scPharmaceuticals Inc.
There is no last downgrade for scPharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of scPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for scPharmaceuticals was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest scPharmaceuticals (SCPH) rating was a reiterated with a price target of $0.00 to $18.00. The current price scPharmaceuticals (SCPH) is trading at is $4.51, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.